Hypera SA (Brazil) Today
| HYPE3 Stock | BRL 19.72 0.37 1.91% |
PerformanceVery Weak
| Odds Of DistressLow
|
Hypera SA is selling for under 19.72 as of the 16th of February 2025; that is 1.91% up since the beginning of the trading day. The stock's lowest day price was 19.38. Hypera SA has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of January 2025 and ending today, the 16th of February 2025. Click here to learn more.
It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. The company has 631.94 M outstanding shares. More on Hypera SA
Moving against Hypera Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Hypera Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hypera SA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hypera SA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) |
Hypera SA (HYPE3) is traded on Sao Paulo Exchange in Brazil and employs 9,000 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 28.34 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hypera SA's market, we take the total number of its shares issued and multiply it by Hypera SA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hypera SA operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 631.94 M outstanding shares.
Hypera SA has accumulated about 2.24 B in cash with 1.4 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.24.
Check Hypera SA Probability Of Bankruptcy
Ownership AllocationHypera SA has a total of 631.94 Million outstanding shares. Hypera SA secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hypera Ownership Details
Hypera SA Risk Profiles
Although Hypera SA's alpha and beta are two of the key measurements used to evaluate Hypera SA's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.28 | |||
| Standard Deviation | 1.72 | |||
| Variance | 2.97 | |||
| Risk Adjusted Performance | (0.03) |
Hypera Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hypera SA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Hypera SA Corporate Directors
| Maria Lacerda | Independent Member of the Board of Directors | Profile | |
| David Coury | Independent Member of the Board of Directors | Profile | |
| Alvado Link | Member of the Board of Directors | Profile | |
| Bernardo Hernandez | Member of the Board of Directors | Profile |
Additional Tools for Hypera Stock Analysis
When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.